Oncotarget

Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas

Retrieved on: 
Monday, June 26, 2023

Despite advances for NHL using combination and targeted therapies, nearly 20% to 40% of patients with certain subtypes still relapse after treatment.

Key Points: 
  • Despite advances for NHL using combination and targeted therapies, nearly 20% to 40% of patients with certain subtypes still relapse after treatment.
  • “We have developed this molecule from initial ideas to first-in-human clinical testing in a highly efficient and rapid manner by leveraging our AI platform, RADR®.
  • Based on the potential of LP-284 for MCL, Lantern was granted an FDA Orphan Drug Designation for LP-284 in MCL.
  • The full journal article can be found on Lantern’s website or at the Oncotarget website .

Insilico Medicine Founder and CEO to Give Keynote on Disease Modeling with AI at PEGS Boston

Retrieved on: 
Friday, May 12, 2023

Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced that Alex Zhavoronkov, PhD, founder and CEO of the Company, will attend the PEGS Boston Summit from May 15-19.

Key Points: 
  • Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced that Alex Zhavoronkov, PhD, founder and CEO of the Company, will attend the PEGS Boston Summit from May 15-19.
  • A team of expert scientists are developing Pharma.AI at the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi, the region’s largest AI-powered biotechnology research center.
  • “We are at an exciting moment in the history of generative AI in drug discovery,” says Zhavoronkov.
  • In total, Insilico has 31 programs across 29 targets, including in fibrosis, oncology, immunology, and central nervous system disorders.

Head of Insilico Medicine’s Hong Kong R&D Center to Give Keynote on AI Drug Discovery at HKUST Big Data Institute

Retrieved on: 
Thursday, May 4, 2023

Hong Kong, May 04, 2023 (GLOBE NEWSWIRE) -- Frank Pun, PhD, Head of the Hong Kong R&D Center of Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven drug discovery company, will give a keynote presentation titled “How AI is Transforming Drug Discoveries” at the Hong Kong University of Science and Technology Big Data Institute Workshop on Big Data and Biomedical & Chemistry Science on May 8, 10am, HKT.

Key Points: 
  • Hong Kong, May 04, 2023 (GLOBE NEWSWIRE) -- Frank Pun, PhD, Head of the Hong Kong R&D Center of Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven drug discovery company, will give a keynote presentation titled “How AI is Transforming Drug Discoveries” at the Hong Kong University of Science and Technology Big Data Institute Workshop on Big Data and Biomedical & Chemistry Science on May 8, 10am, HKT.
  • The Company’s software is trained on aging and focused on diseases with high unmet need, and two of its AI-designed drugs have reached clinical trials.
  • Insilico first proved the concept of an AI drug discovery engine in 2016 – screening 72 million compounds and identifying candidate molecules with anti-cancer properties in a paper published in Oncotarget .
  • Dr. Pun leads a team of application scientists in Hong Kong who are further developing PandaOmics , the AI-enabled biological target discovery engine of Insilico’s end-to-end platform and has published widely in top peer-reviewed journals related to his research in AI drug discovery.

Agilent Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer

Retrieved on: 
Tuesday, December 13, 2022

3,4 ctDx FIRST provides NSCLC patients and their oncologists with a new minimally invasive blood test to help clarify precision treatment options.

Key Points: 
  • 3,4 ctDx FIRST provides NSCLC patients and their oncologists with a new minimally invasive blood test to help clarify precision treatment options.
  • The ctDx FIRST assay uses novel propriety technology to detect genomic alterations in circulating tumor DNA (ctDNA) from plasma.
  • We appreciate the opportunity to partner with companies like Agilent who are committed to creating more opportunities for decision medicine for people living with cancer.
  • The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.

GoPath® Diagnostics Launches FDA-Cleared CGP Test under OncoTarget® 500

Retrieved on: 
Tuesday, May 31, 2022

BUFFALO GROVE, Ill., May 31, 2022 /PRNewswire-PRWeb/ -- OncoTarget® 500 assesses cancer pathology by analyzing over 500 genes to detect genetic alterations associated with cancer growth. With OncoTarget® 500, oncologists and researchers may effectively determine the unique genomic profile of individual tumors to determine the most suitable therapies for optimal medical outcomes in a timely manner.

Key Points: 
  • BUFFALO GROVE, Ill., May 31, 2022 /PRNewswire-PRWeb/ -- OncoTarget 500 assesses cancer pathology by analyzing over 500 genes to detect genetic alterations associated with cancer growth.
  • With OncoTarget 500 and additional GoPath test offerings such as OncoTracking and GeneticsNow, cancer specialists can determine the latest therapy options, risk of recurrence and metastasis, and the genetic predisposition for their patients.
  • GoPath Diagnostics is a CAP-accredited, CLIA-certified laboratory that offers advanced cancer diagnostics that provide detailed insights throughout a patient's recovery journey.
  • GoPath Diagnostics provides easy accessibility and affordability for its tests and services, with OncoTarget 500 covered by major insurance providers and Medicare.

Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer

Retrieved on: 
Friday, December 17, 2021

New modalities in colorectal cancer screening, such as a routine, accurate blood test like the one being studied in the ECLIPSE study, has the potential to increase screening rates dramatically, said AmirAli Talasaz, Guardant Health co-CEO.

Key Points: 
  • New modalities in colorectal cancer screening, such as a routine, accurate blood test like the one being studied in the ECLIPSE study, has the potential to increase screening rates dramatically, said AmirAli Talasaz, Guardant Health co-CEO.
  • We look forward to evaluating the data from the ECLIPSE study to increase our understanding of blood-based screening in patients at average risk for colorectal cancer.
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.
  • Cancer.

COVID-19 Severity and Risk Predicted by New Metabolism-Based Blood Test

Retrieved on: 
Wednesday, December 1, 2021

Blood samples were obtained from each patient and studied for biochemical composition using quantitative mass spectrometry.

Key Points: 
  • Blood samples were obtained from each patient and studied for biochemical composition using quantitative mass spectrometry.
  • This technique allowed researchers to measure minute quantities of metabolites in the blood.
  • Investigators identified metabolic signatures that could distinguish mild COVID-19 infection from more severe and lethal forms of the disease.
  • Metabolomycs, Inc is a California-based corporation that applies metabolic signatures measured by mass spectrometry to study human health and disease.

Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel

Retrieved on: 
Monday, November 1, 2021

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target date for ciltacabtagene autoleucel (cilta-cel) to February 28, 2022.

Key Points: 
  • Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target date for ciltacabtagene autoleucel (cilta-cel) to February 28, 2022.
  • The Biologics License Application (BLA) was submitted by Legend Biotechs collaboration partner Janssen Biotech, Inc. (Janssen).
  • In December 2017, Legend Biotech, Inc. entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel.
  • Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers

Retrieved on: 
Friday, September 17, 2021

New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute, showed promising early clinical activity in patients with several types of advanced solid tumors.

Key Points: 
  • New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute, showed promising early clinical activity in patients with several types of advanced solid tumors.
  • DS-7300 was tolerated across all dose levels (0.8 mg/kg -16.0 mg/kg) with no dose-limiting toxicities observed in 70 patients enrolled.
  • Stable disease has been reported in an additional 32 patients including 24 patients who are still being treated with various doses of DS-7300 as of data cut-off of July 21, 2021.
  • Patients enrolled in the dose escalation study received a median of four prior lines of therapy (range, 1-10).

Telix In-Licences Novel Tumour Microenvironment PET Tracer

Retrieved on: 
Thursday, September 9, 2021

The investigational-stage PET radiotracer, known as [18F]-3-fluoro-2-hydroxypropionate or [18F]-FLac, has demonstrated promise for imaging lactate metabolism in oxygenated tumours and tumour microenvironment (TME).

Key Points: 
  • The investigational-stage PET radiotracer, known as [18F]-3-fluoro-2-hydroxypropionate or [18F]-FLac, has demonstrated promise for imaging lactate metabolism in oxygenated tumours and tumour microenvironment (TME).
  • The most widely used commercial PET tracer today is 2-deoxy-2-[18F]-fluoro-D-glucose ([18F]-FDG), a radiolabelled glucose molecule that is used in ~90% of scans.
  • Imaging with [18F]-FDG PET is used to determine sites of abnormal glucose metabolism and can characterise and localise many tumour types.
  • Telix Chief Scientist, Dr. Michael Wheatcroft added, This is a very exciting and novel tumour tracer with the potential to complement the universal PET agent [18F]-FDG to improve the detection of all tumours.